Investing in Delcath Systems, Inc. (DCTH)  ➔  Intrinsic value

Prev. close$10.19 
ModelValueUpside
Chepakovich$0.30-97%
Graham-Dodd$0.00-100%
Graham$0.00-100%
Previous Close$10.19  
Valuation MethodValuePotential 
Chepakovich Model$0.30-97%recalculate
Graham-Dodd$0.00-100%recalculate
Graham Formula$0.00-100%recalculate

Latest news

Company description

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers. The company's lead product candidate is the melphalan hydrochloride for injection for use with the Delcath hepatic delivery system to administer high-dose chemotherapy to the liver. Its Phase III clinical trial products include FOCUS Trial for the patients with hepatic dominant ocular melanoma; and ALIGN Trial for intrahepatic cholangiocarcinoma. The company also offers melphalan hydrochloride under the Delcath Hepatic CHEMOSAT Delivery System for Melphalan name in Europe. The company was founded in 1988 and is headquartered in New York, New York.